TrialHuman vaccines2011

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.

Mark H Einstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.